Neurocrine Biosciences (NBIX) Common Equity (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Common Equity for 17 consecutive years, with $3.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 37.09% year-over-year to $3.7 billion; the trailing twelve-month figure through Jun 2026 stood at $3.7 billion (up 37.09% YoY), and the FY2025 full-year result was $3.3 billion, up 25.62% from the prior year.
• Common Equity grew to $3.7 billion in Q2 2026 per NBIX's latest filing, from $3.4 billion in the prior quarter.
• Across five years, Common Equity topped out at $3.7 billion in Q2 2026 and bottomed at $1.4 billion in Q1 2022.
• Historically, Common Equity has averaged $2.4 billion across 5 years, with a median of $2.4 billion in 2024.
• The sharpest annual moves came in 2024 and 2025: Common Equity soared 41.65% in 2024, then increased 6.27% in 2025.
• Over 5 years, Common Equity stood at $1.7 billion in 2022, then soared by 30.69% to $2.2 billion in 2023, then gained by 16.03% to $2.6 billion in 2024, then rose by 25.62% to $3.3 billion in 2025, then climbed by 13.54% to $3.7 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $3.7 billion, $3.4 billion, and $3.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.